ES2098672T3 - Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3. - Google Patents

Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.

Info

Publication number
ES2098672T3
ES2098672T3 ES93306978T ES93306978T ES2098672T3 ES 2098672 T3 ES2098672 T3 ES 2098672T3 ES 93306978 T ES93306978 T ES 93306978T ES 93306978 T ES93306978 T ES 93306978T ES 2098672 T3 ES2098672 T3 ES 2098672T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
compositions containing
vitamin derivatives
stabilized pharmaceutical
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93306978T
Other languages
English (en)
Inventor
David Isaac Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2098672T3 publication Critical patent/ES2098672T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA COMPOSICION FARMACEUTICA DE ESTADO SOLIDO QUE COMPRENDE AL MENOS LOS INGREDIENTES A), B) Y C) DE LOS INGREDIENTES SIGUIENTES A), B), C) Y D), NOMINALMENTE: A) AL MENOS UN COMPONENTE ACTIVO SELECCIONADO ENTRE DERIVADOS FARMACOLOGICAMENTE ACTIVOS DE LA VITAMINA D2 Y LA VITAMINA D3; B) AL MENOS UN ANTIOXIDANTE FARMACOLOGICAMENTE ACEPTABLE; C) AL MENOS UN ESTABILIZADOR DE POLIOXIALQUIL FARMACOLOGICAMENTE ACEPTABLE; D) AL MENOS UN EXCIPIENTE FARMACEUTICO SOLIDO O UN PORTADOR EN UNA CANTIDAD SUFICIENTE PARA IMPARTIR LAS CARACTERISTICAS DE SOLIDO A LA COMPOSICION.
ES93306978T 1992-09-18 1993-09-03 Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3. Expired - Lifetime ES2098672T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10322492A IL103224A (en) 1992-09-18 1992-09-18 Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3

Publications (1)

Publication Number Publication Date
ES2098672T3 true ES2098672T3 (es) 1997-05-01

Family

ID=11064050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93306978T Expired - Lifetime ES2098672T3 (es) 1992-09-18 1993-09-03 Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.

Country Status (12)

Country Link
US (2) US5565442A (es)
EP (1) EP0588539B1 (es)
JP (1) JP3464691B2 (es)
AT (1) ATE148630T1 (es)
AU (1) AU667742B2 (es)
CA (1) CA2106423C (es)
DE (1) DE69307977T2 (es)
DK (1) DK0588539T3 (es)
ES (1) ES2098672T3 (es)
GR (1) GR3023127T3 (es)
IL (1) IL103224A (es)
ZA (1) ZA936835B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
JP2656448B2 (ja) * 1994-07-25 1997-09-24 マイクロアルジェコーポレーション株式会社 カルシウムを主成分とする健康食品
DE19710054A1 (de) * 1997-03-12 1998-09-17 Merck Patent Gmbh Pharmazeutische Zubereitung
ITFI970184A1 (it) * 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
AU2001278956B2 (en) * 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20080274209A1 (en) * 2002-11-04 2008-11-06 Integritas Pharma, Inc. Methods of treating inflammation
US6855341B2 (en) * 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US7700365B2 (en) 2004-10-29 2010-04-20 Mayo Foundation For Medical Education And Research Vitamin D deficiencies
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
JP5492099B2 (ja) * 2008-03-12 2014-05-14 シトクロマ インコーポレイテッド 安定化１，２５−ジヒドロキシビタミンｄ２及びその製造方法
WO2010019566A2 (en) * 2008-08-11 2010-02-18 Mayo Foundation For Medical Education And Research Methods for determining levels of 1,25 dihydroxy vitamin d2 and d3
NZ591810A (en) * 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
SG2014006324A (en) 2009-01-27 2014-03-28 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106265695B (zh) 2009-08-14 2021-05-07 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
AU2014201820B2 (en) 2013-03-27 2016-05-19 Psm Healthcare Limited Stabilized vitamin D formulations
NZ714801A (en) 2013-05-29 2021-07-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d
US11071743B1 (en) * 2015-01-16 2021-07-27 Gregory M. Fahy Effective, non-toxic treatments for brain cancer
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932634A (en) * 1973-06-28 1976-01-13 Pfizer Inc. High potency vitamin water dispersible formulations
JPS58206533A (ja) * 1982-05-27 1983-12-01 Teijin Ltd 活性型ビタミンｄ↓３誘導体組成物及びそれを活性成分とする薬剤
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
CA1317546C (en) * 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
JPS62149619A (ja) * 1985-09-05 1987-07-03 Teijin Ltd 活性型ビタミンｄ３類注射用組成物
DD266099A1 (de) * 1987-09-28 1989-03-22 Jenapharm Veb Verfahren zur herstellung von stabilen waessrigen vitamin-d-loesungen
JPH0331257Y2 (es) * 1987-10-31 1991-07-02
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja) * 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
DE69005897D1 (de) * 1989-05-18 1994-02-24 Hoffmann La Roche Dehydrocholecalciferolderivate.
ATE104554T1 (de) * 1990-01-10 1994-05-15 Hoffmann La Roche Topische praeparate.
JP2963718B2 (ja) * 1990-03-06 1999-10-18 グレラン製薬株式会社 ビタミンｄ▲下３▼類含有製剤
JP2787364B2 (ja) * 1990-03-29 1998-08-13 大塚製薬株式会社 脂溶性ビタミン注射液
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JP2974734B2 (ja) * 1990-07-12 1999-11-10 中外製薬株式会社 安定な活性型ビタミンｄ▲下３▼類製剤
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物

Also Published As

Publication number Publication date
EP0588539A1 (en) 1994-03-23
CA2106423A1 (en) 1994-03-19
GR3023127T3 (en) 1997-07-30
ATE148630T1 (de) 1997-02-15
CA2106423C (en) 2005-02-22
IL103224A (en) 1998-08-16
IL103224A0 (en) 1993-02-21
US5804573A (en) 1998-09-08
AU4740893A (en) 1994-03-24
ZA936835B (en) 1994-04-14
US5565442A (en) 1996-10-15
DK0588539T3 (da) 1997-03-10
JPH06219952A (ja) 1994-08-09
AU667742B2 (en) 1996-04-04
JP3464691B2 (ja) 2003-11-10
DE69307977D1 (de) 1997-03-20
DE69307977T2 (de) 1997-08-28
EP0588539B1 (en) 1997-02-05

Similar Documents

Publication Publication Date Title
ES2098672T3 (es) Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
TW355683B (en) Composition containing micronized nebivolol
EP0948965A4 (en) STABLE MEDICAL COMPOSITIONS CONTAINING 4,5-EPOXYMORPHINE DERIVATIVES
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
IL106562A0 (en) Pharmaceutical and/or cosmetic compositions and the use thereof
CA2066924A1 (fr) Utilisation du pyrrolidone carboxylate de lysine et/ou du pyrrolidone carboxylate d'arginine comme substance antioxydante dans une composition cosmetique ou pharmaceutique
ZA911728B (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
ES2062375T3 (es) Composiciones farmaceuticas que contienen un complejo de zinc.
KR950007857A (ko) 경구투여용 라파마이신 제제
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
GB2021409A (en) Pharmaceutical composition
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
MX9204815A (es) Hexahidrobenzo[f]quinolinonas y formulacion farmaceutica que las comprende.
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
AU4132693A (en) Substituted 1,2,4-triazine-3,5-dione derivative and anticoccidial drug composition containing the same as active component
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
CA2103667A1 (fr) Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4
AU5284999A (en) New injectable formulations containing ramoplanin
IL103856A0 (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them
DK0508311T3 (da) Injicerbare præparater indeholdende 2-oxindol-1-carboxamidderivater
IT1254453B (it) Composizioni farmaceutiche per uso orale a base di glutatione ridotto
IT1254938B (it) Derivati otticamente attivi della n-imminoalchil-n'-((2-idrossi- 2-fenil-2-cicloesil)-etil)-piperazina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 588539

Country of ref document: ES